These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1623911)

  • 21. Quinine pharmacokinetics in chronic haemodialysis patients.
    Roy L; Bannon P; Villeneuve JP;
    Br J Clin Pharmacol; 2002 Dec; 54(6):604-9. PubMed ID: 12492607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure.
    White LO; MacGowan AP; Mackay IG; Reeves DS
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():65-72. PubMed ID: 3182464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics of single doses of metoclopramide in renal failure.
    Bateman DN; Gokal R; Dodd TR; Blain PG
    Eur J Clin Pharmacol; 1981; 19(6):437-41. PubMed ID: 7250177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ofloxacin pharmacokinetics in chronic renal failure and dialysis.
    Lameire N; Rosenkranz B; Malerczyk V; Lehr KH; Veys N; Ringoir S
    Clin Pharmacokinet; 1991 Nov; 21(5):357-71. PubMed ID: 1773550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis.
    Spigset O; Hägg S; Stegmayr B; Dahlqvist R
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):699-703. PubMed ID: 11214779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of zopiclone pharmacokinetics in patients with impaired renal function and normal subjects. Effect of hemodialysis.
    Marc-Aurele J; Caille G; Bourgoin J
    Sleep; 1987; 10 Suppl 1():22-6. PubMed ID: 3438644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency.
    Humbert G; Leroy A; Fillastre JP; Godin M
    Chemotherapy; 1979; 25(4):189-95. PubMed ID: 456077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin.
    Davies BE; Boon R; Horton R; Reubi FC; Descoeudres CE
    Br J Clin Pharmacol; 1988 Oct; 26(4):385-90. PubMed ID: 3190988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis.
    Hildebrand M; Krause W; Fabian H; Koziol T; Neumayer HH
    Int J Clin Pharmacol Res; 1990; 10(5):285-92. PubMed ID: 1706685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of aztreonam in patients with chronic renal failure.
    Fillastre JP; Leroy A; Baudoin C; Humbert G; Swabb EA; Vertucci C; Godin M
    Clin Pharmacokinet; 1985; 10(1):91-100. PubMed ID: 4038635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of verapamil in patients with renal failure.
    Mooy J; Schols M; v Baak M; v Hooff M; Muytjens A; Rahn KH
    Eur J Clin Pharmacol; 1985; 28(4):405-10. PubMed ID: 4029246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of cefodizime in normal individuals and in patients with renal failure.
    el Guinaidy MA; Nawishy S; Abd el Bary M; Sabbour MS
    Chemotherapy; 1991; 37(2):77-85. PubMed ID: 2032473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration.
    De Bock V; Verbeelen D; Maes V; Sennesael J
    Nephrol Dial Transplant; 1989; 4(7):635-9. PubMed ID: 2510061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.
    al-Ghamdi MS; al-Mohanna FA; al-Mustafa ZH; al-Saeed IS
    Eur J Clin Pharmacol; 1992; 43(2):197-9. PubMed ID: 1425878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacokinetics of azlocillin in chronic renal failure and hemodialysis patients].
    Fillastre JP; Humbert G; Leroy A; Godin M
    Presse Med; 1984 Mar; 13(13):797-801. PubMed ID: 6231597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
    Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tinidazole pharmacokinetics in severe renal failure.
    Robson RA; Bailey RR; Sharman JR
    Clin Pharmacokinet; 1984; 9(1):88-94. PubMed ID: 6692632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
    Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
    Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure.
    Kradjan WA; Martin TR; Delaney CJ; Blair AD; Cutler RE
    Nephron; 1982; 32(1):40-4. PubMed ID: 7177275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rimantadine pharmacokinetics in healthy subjects and patients with end-stage renal failure.
    Capparelli EV; Stevens RC; Chow MS; Izard M; Wills RJ
    Clin Pharmacol Ther; 1988 May; 43(5):536-41. PubMed ID: 3365917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.